Abstract
There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Current Drug Targets
Title: How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Volume: 12 Issue: 10
Author(s): Raja Affendi Raja Ali and Laurence John Egan
Affiliation:
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Abstract: There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Export Options
About this article
Cite this article as:
Affendi Raja Ali Raja and John Egan Laurence, How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818270
DOI https://dx.doi.org/10.2174/138945011796818270 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design MicroRNAs Contribute to Hepatocellular Carcinoma
Mini-Reviews in Medicinal Chemistry Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets The Role of Trophoblast Nutrient and Ion Transporters in the Development of Pregnancy Complications and Adult Disease
Current Vascular Pharmacology Patent Selections:
Recent Patents on Medical Imaging <i>In Silico</i> Investigation: Opening Doors to Novel Thymidylate Synthase Inhibitors
Current Enzyme Inhibition Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning
Current Medicinal Chemistry Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Current Cancer Drug Targets New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice
Protein & Peptide Letters Electroporation Advances in Large Animals
Current Gene Therapy Flavonoids as Prospective Aromatase Inhibitors in Breast Cancer Prevention/ Therapy
Current Molecular Pharmacology Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Current Topics in Medicinal Chemistry